Royalty Pharma (NASDAQ:RPRX) said it has acquired a royalty interest in two of Nuvalent’s lead cancer programs for as much as $315 million, adding long-dated exposure to a pair of next-generation tyrosine kinase inhibitors targeting ALK- and ROS1-altered non-small cell lung cancer.
The deal covers a low-single-digit royalty on global sales of neladalkib and zidesamtinib, with the payment stream expected to extend through roughly 2041 to 2042.
Analyst consensus forecasts peak sales of about $3.5 billion for neladalkib and $1.9 billion for zidesamtinib by 2035, underscoring the commercial potential Royalty Pharma is tapping into.
Neladalkib delivered positive pivotal data in November and is already in a Phase 3 trial in treatment-naïve patients.
Zidesamtinib is under FDA review with a Prescription Drug User Fee Act target date of Sept. 18, 2026, while a Phase 1/2 trial continues in the frontline setting.
The acquisition continues Royalty Pharma’s strategy of expanding its portfolio with royalties on late-stage or commercial-ready assets that offer multidecade revenue duration and exposure to high-value therapeutic categories such as oncology.